Form 4: Immunovant COO Melanie Gloria Reports Stock and Option Awards

Melanie Gloria, Chief Operating Officer of Immunovant, Inc., reports the acquisition of restricted stock units and stock options.

Summary

• On April 1, 2025, Melanie Gloria, the Chief Operating Officer of Immunovant, Inc., was granted 76,181 restricted stock units (RSUs) and options to purchase 107,297 shares of common stock.
• The RSUs were granted under the company's 2019 Equity Incentive Plan and each RSU represents the right to receive one share of common stock upon vesting.
• 25% of the RSUs will vest on April 1, 2026, with the remaining units vesting in equal quarterly installments over the following three years, contingent upon continuous service.
• The stock options have an exercise price of $15.20 and also vest as to 25% on April 1, 2026, with the remainder vesting in 36 equal monthly installments over three years, subject to continuous service.
• Following these transactions, Ms. Gloria directly owns 186,137 shares of Immunovant common stock and 107,297 stock options.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of equity is a standard practice and generally viewed favorably as it aligns management interests with shareholders.

Positives

• The grant of RSUs and stock options aligns Ms. Gloria's interests with those of Immunovant's shareholders, incentivizing her to contribute to the company's long-term success.
• The vesting schedule encourages continued service and commitment from the COO.

Future Outlook

The document does not contain specific forward-looking statements, but the equity grants suggest an expectation of continued service and contribution from the COO.

Industry Context

Equity grants are a common practice in the biotechnology industry to attract, retain, and incentivize key executives. This grant is consistent with industry norms for aligning management interests with shareholder value.

Comparison to Industry Standards

• Equity compensation packages for biotech executives typically include a mix of stock options and restricted stock units, vesting over a period of 3-4 years.
• The vesting schedule and terms of these grants appear consistent with industry standards for companies of Immunovant's size and stage of development.
• Comparable companies such as Argenx and UCB also utilize similar equity-based compensation strategies for their executive teams.

Stakeholder Impact

• Shareholders may view the equity grants positively as they incentivize management to increase shareholder value.
• Employees may see the grants as a sign of the company's commitment to its leadership team.

Key Dates

Keywords

Immunovant, Melanie Gloria, stock options, restricted stock units, RSUs, IMVT, equity incentive plan, beneficial ownership, Form 4, COO